Freya Biosciences is a clinical-stage women's health company pioneering a new class of microbial immunotherapies.
Freya Biosciences has raised $11.8M in total funding. The most recent round was Series A. The last funding was announced in November 2024.
Freya Biosciences's investors include Bill & Melinda Gates Foundation, Sofinnova Partners, OMX Ventures, Angelini Ventures, Indaco Venture Partners.
Freya Biosciences is headquartered in Boston, United States.
Freya Biosciences is a clinical-stage women's health company pioneering a new class of microbial immunotherapies.
Freya Biosciences is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Freya Biosciences — Funding & Investors." VCBacked, November 19, 2024, https://www.vcbacked.co/company/freya-biosciences. Accessed July 31, 2026.
VCBacked. (2024). Freya Biosciences — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/freya-biosciences
{{cite web |title=Freya Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/freya-biosciences |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated